Neuralink
Brain-computer interface implants for people with paralysis, in clinical trials
100X Meter Early
Think Neuralink could go 100X?
Give it a push. One tap per reader each day; the meter tracks buzz here, not quality.
Tell your network you backed Neuralink early
Download share card
For founders
Share your listing
Everything you need to send people to Neuralink on 100xFounder. Links carry share tags so you can see the visits in your own analytics.
Badge for your site
Shows your live 100X Meter level and links to this page.
Share card
A 1080×1350 image with your current level, sized for Instagram and LinkedIn.
Download share cardReady-to-post captions
We're listed on 100xFounder. Neuralink now has a page on the 100X Meter, where readers back the startups they believe in with one tap a day.
If you've used Neuralink, a tap or a short review there would mean a lot to the team: https://100xfounder.com/startup/neuralink/?utm_source=linkedin&utm_medium=share&utm_campaign=founder-kit
X
Neuralink is on the 100xFounder 100X Meter ⚡ Think we could go 100X? One tap a day helps: https://100xfounder.com/startup/neuralink/?utm_source=x&utm_medium=share&utm_campaign=founder-kit
Hi! Neuralink is listed on 100xFounder. If you like what we're building, tap "100X it" on our page (takes two seconds, once a day): https://100xfounder.com/startup/neuralink/?utm_source=whatsapp&utm_medium=share&utm_campaign=founder-kit
Invite your users to back you on the 100X Meter
Each reader can tap once a day. Send this to your users, community or newsletter.
What Neuralink does
Neuralink is a neurotechnology company developing brain-computer interfaces: devices implanted in the brain that read neural signals and turn them into commands for a computer or phone. It was founded in 2016, with Elon Musk among its founders. It also builds its own surgical robot to place the implant.
Its first product, called Telepathy, is aimed at people with paralysis, letting them move a cursor and type by thought. In a post on 28 January 2026 marking two years of human trials, Neuralink said 21 participants, whom it calls Neuralnauts, were enrolled in its trials worldwide, that the trial had grown from three participants in 2024 to several a month in 2025, and that it had seen no serious device-related adverse events. It said some participants type at up to 40 words a minute, and that a separate trial called VOICE aims to restore speech. These are the company’s own figures and have not been independently verified.
A second device, Blindsight, is meant to restore some vision to people who have lost their sight. The US Food and Drug Administration gave it a Breakthrough Device designation in 2024, and in May 2025 Neuralink received another for restoring communication to people with severe speech impairment, according to reporting on its funding.
On 2 June 2025 Neuralink announced a $650 million Series E. Investors included ARK Invest, Founders Fund, Sequoia Capital and Thrive Capital, TechCrunch reported, and Semafor put the pre-money valuation at about $9 billion.
Neuralink has no product on sale and no published price. Its devices are available only to people enrolled in its clinical trials.
This page is research, not a review: Neuralink has no product we could try. It brings together Neuralink’s own website and the reporting linked under Sources, and says where each fact comes from.
What people use Neuralink for
- Controlling a computer cursor and typing by thought (Telepathy, in trials)
- Restoring communication for people with severe speech impairment (VOICE trial)
- Restoring some vision for people who are blind (Blindsight, in development)
Who Neuralink is for
- people with quadriplegia from spinal cord injury or ALS who may qualify for its trials
- researchers, clinicians and investors following brain-computer interfaces
- anyone looking to buy a device: nothing is for sale
- people who want a non-invasive option, since Neuralink's device requires brain surgery
Neuralink pros and cons
- Large funding base for long clinical programmes
- Publishes regular trial updates on its own site
- Requires brain surgery
- Performance figures come from the company and are not independently verified
Neuralink alternatives and how they compare
Other companies building brain-computer interfaces. None sells a consumer product either.
| Product | What it is | Starts at | Reviews | How it differs from Neuralink |
|---|---|---|---|---|
| Neuralink this page | Brain-computer interface implants for people with paralysis, in clinical trials | Not for sale: clinical trials only | No reviews yet | — |
| Synchron | BCI delivered through a blood vessel | — | — | Its Stentrode is placed through the jugular vein rather than by opening the skull. |
| Precision Neuroscience | Thin-film electrode array on the brain's surface | — | — | Sits on the surface of the brain instead of threads inserted into it. |
| Blackrock Neurotech | Utah-array electrodes used in academic BCI research | — | — | Its arrays have been used in research implants for many years. |
| Paradromics | High-data-rate implanted BCI | — | — | Focused first on restoring speech. |
Neuralink reviews
Write a review
Thanks — share your take?
Frequently asked questions
Can I buy a Neuralink implant?
No. Neuralink has no product on sale. Its implants are available only to people enrolled in its clinical trials.
How many people have a Neuralink implant?
Neuralink said on 28 January 2026 that 21 participants were enrolled in its trials worldwide.
What is Blindsight?
A Neuralink device in development to restore some vision to blind people. The FDA gave it a Breakthrough Device designation in 2024.
How much money has Neuralink raised?
Its latest announced round was a $650 million Series E on 2 June 2025. Semafor put the pre-money valuation at about $9 billion.
Sources (6), checked 15 October 2026
- Neuralink: Two Years of Telepathy
- Neuralink: Telepathy trial
- TechCrunch: Neuralink closes a $650M Series E
- Becker's Hospital Review: Neuralink secures $650M
- Maginative: Neuralink raises $650M
- Wikipedia: Neuralink (founding)
We list Neuralink from public sources and are not affiliated with it. Spotted something wrong? Tell us.